GSK-103478



Assess the immunogenicity, safety & reactogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (6-12 weeks of age at first dose) previously uninfected with human rotavirus
Rotavirus Vaccine
103478
NCT00134732
Infections, Rotavirus
Phase 3
 
An annotated case report form is not available for this study. A blank case report form will be provided.
January 2014